Clinical Trials Logo

Clinical Trial Summary

The purpose of this clinical study is to determine whether EFT (Emotional Freedom Techniques) is effective in alleviating nausea and vomiting in pregnant women with hyperemesis. Additionally, the study aims to gather information on the safety of EFT application. The primary questions it seeks to answer are: Does EFT reduce nausea and vomiting in pregnant women with hyperemesis? Is EFT applicable for use in pregnant women with hyperemesis? Researchers will compare the effectiveness of EFT to traditional nursing education on non-pharmacological interventions for preventing nausea and vomiting in pregnant women with hyperemesis. Participants: Pre-EFT application survey scale questions will be asked to the pregnant women with hyperemesis. EFT will be applied once by the researcher to the pregnant women with hyperemesis. For control, the same survey scale questions will be asked to the same pregnant women two days after the EFT application for post-test purposes. For control, the same survey scale questions will be asked to the same pregnant women seven days after the EFT application for post-test purposes. The same procedures will be applied in the same manner to the control group that will receive education.


Clinical Trial Description

Type of Research: It is planned to be randomized, controlled and experimental. Place and Characteristics of the Research: The research will be carried out in the women health and diseases service and Gynecology polyclinics of Bezmialem Vakif University Faculty of Medicine Central Hospital. Population and Sample of the Research:The sample size was determined as a minimum of 74 people in total using the G Power 3.1 method. The effect size was determined using the t test values in the reference study in which the scale was used with a similar patient group. Criteria for Inclusion in the Study:Pregnant women who are between 6 and 14 weeks of gestation, aged between 20 and 40 years old, and have complaints of nausea and vomiting are eligible for the study. These participants should report their discomfort as 5 or above on the VAS scale. Additionally, they must not have been diagnosed with a high-risk pregnancy or any psychological disorders. Lastly, they must voluntarily agree to participate in the study. Criteria for Exclusion from the Study: Exclusion criteria are the presence of coordination and language problems in the pregnant woman and her desire to leave the study at any time or not to participate. Survey Scales Descriptive Information Form: The pregnancy information form, prepared in line with the literature review conducted by the researchers, includes socio-demographic (age of the pregnant woman, education and employment status, income level, family type and place of residence), obstetric (current gestational week and pregnancy history), psychosocial information. It consists of questions about social and medical history (pregnancy desire), whether there is a chronic disease) and VAS Scale. VAS is a measurement tool used to measure both pain intensity and pain relief, which is simple, effective and repeatable and requires minimal tools. 2. Pregnancy-Specific Nausea and Vomiting Severity Scale (PUQE-24): its form specific to the pregnancy period that evaluates nausea and vomiting for the last 12 hours. It was later reported that it would be more appropriate to evaluate the last 24 hours for clinical use, as the last 12 hours sometimes include the sleep period in terms of nausea and vomiting in pregnant women. Thereupon, the Pregnancy-Unique Quantification of Emesis (PUQE-24) Scale was developed and evaluate the severity of pregnancy-specific nausea and vomiting in the last 24 hours. Its Turkish validity and reliability were conducted. Pregnancy-Specific Nausea and Vomiting Severity Scale (PUQE-24) consists of 3 questions:duration of nausea or stomach discomfort, number of vomiting episodes, and number of retching episodes. Answers to the questions are scored between 1 and 5 points. The total score of the scale is obtained by the sum of the scores of the answers given to the questions. The lowest possible score that can be obtained from the scale is 3 and the highest score is 15. If the total score obtained as a result of the PUQE-24 scoring system is 3-6, it is considered mild, 7-12 is considered moderate, and 13-15 is considered severe nausea and vomiting. The scale has no subdimensions. Cronbacha alpha value of the Turkish version of the scale is 0.75. 3.World Health Organization Quality of Life Scale: The WHOQOL-100 scale was developed with the participation of 15 centers from many countries. This scale allows cross-cultural comparisons. WHOQOL-100 was later abbreviated as WHOQOLBREF. WHOQOL-BREF consists of four sub-dimensions: physical domain, spiritual domain, social domain and environmental domain. The validity and reliability of the World Health Organization Quality of Life Scale 31 Short Form-Turkish Version (WHOQOL-BREF-TR) in Turkey was determined. WHOQOL-BREF-TR used in this study consists of 27 questions. For each question, there are options that can be scored between 1 and 5. The scale does not have a total score. The score range that can be obtained from each other sub-dimension is obtained by multiplying the arithmetic mean of that sub-dimension by 4. The score range that can be received for each sub-dimension is between 4-20. Increasing scores from the subscales indicate that the quality of life also increases ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06442813
Study type Interventional
Source Bezmialem Vakif University
Contact Merve MESEDUZU, LECTURER
Phone 800-555-5555
Email mervemeseduzu@gmail.com
Status Not yet recruiting
Phase N/A
Start date June 10, 2024
Completion date August 30, 2024

See also
  Status Clinical Trial Phase
Completed NCT03442582 - Afluria Pregnancy Registry
Terminated NCT02161861 - Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study N/A
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Enrolling by invitation NCT05415371 - Persistent Poverty Counties Pregnant Women With Medicaid N/A
Completed NCT04548102 - Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman N/A
Completed NCT03218956 - Protein Requirement During Lactation N/A
Completed NCT02191605 - Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy N/A
Completed NCT02223637 - Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
Recruiting NCT06049953 - Maternal And Infant Antipsychotic Study
Completed NCT02577536 - PregSource: Crowdsourcing to Understand Pregnancy
Not yet recruiting NCT06336434 - CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy Phase 1/Phase 2
Not yet recruiting NCT04786587 - Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
Not yet recruiting NCT05412238 - Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months N/A
Not yet recruiting NCT05028387 - Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
Completed NCT02683005 - Study of Hepatitis C Treatment During Pregnancy Phase 1
Completed NCT02783170 - Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women Phase 4
Recruiting NCT02507180 - Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
Recruiting NCT02619188 - Nutritional Markers in Normal and Hyperemesis Pregnancies N/A
Recruiting NCT02564250 - Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women N/A
Completed NCT02520687 - Effects of Dietary Nitrate in Hypertensive Pregnant Women Phase 1